Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.48 |
| ▸ | MMP13 | P45452 | 6/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316551 | 0.89 | TAS2R14 (0.45) | TAS2R14PGRKEAP1NFE2L2CYP11B1 | |
| SCHEMBL4313198 | 0.88 | TAS2R14 (0.44) | TAS2R14PGRKEAP1NFE2L2KDM4E | |
| SCHEMBL4310251 | 0.87 | MMP2 (0.52) | MMP2MMP13TAS2R14PGRKEAP1 | |
| SCHEMBL4310204 | 0.85 | TAS2R14 (0.45) | MMP2TAS2R14PGRKEAP1NFE2L2 | |
| SCHEMBL4313668 | 0.85 | TAS2R14 (0.45) | TAS2R14PGRKEAP1NFE2L2CYP11B1 | |
| SCHEMBL4318699 | 0.84 | CYP11B1 (0.48) | MMP2TAS2R14PGRKEAP1NFE2L2 | |
| SCHEMBL4318692 | 0.84 | CYP11B1 (0.48) | MMP2TAS2R14PGRKEAP1NFE2L2 | |
| SCHEMBL8231945 | 0.84 | MMP2 (0.51) | MMP2MMP13TAS2R14PGRKEAP1 | |
| SCHEMBL4316391 | 0.82 | MMP2 (0.62) | MMP2MMP13MMP9 | |
| SCHEMBL11948509 | 0.82 | MMP2 (0.53) | MMP2MMP13TAS2R14KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001838-B1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2001838-B1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2597083-A2 | Selective hydroxamate based MMP inhibitors | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2597083-A2 | Selective hydroxamate based MMP inhibitors | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8314148-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314148-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314148-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8232427-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232427-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232427-B2 | Selective hydroxamate based MMP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-2001838-A2 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007117981-A2 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117981-A2 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318511-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | MMP13, MMP11, MMP14 | MMP2 15/4885MMP13 1/4885TAS2R14 2291/4885 |
| US-20120225882-A1 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS | MMP13, MMP11, MMP14 | MMP2 15/4885MMP13 1/4885TAS2R14 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.